Paper Details

  1. Home
  2. Paper Details

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Author: AhlbornMiriam, BalabanovStefan, BauesChristian, BorchmannPeter, BröckelmannPaul J, DiehlVolker, DierlammJudith, DietleinMarkus, EichHans, EngertAndreas, FuchsMichael, GreilRichard, HalbsguthTeresa V, HallekMichael, HüttmannAndreas, KellerUlrich, KerkhoffAndrea, KlimmBeate, KobeCarsten, KuhnertGeorg, MarnitzSimone, MartinSonja, MeissnerJulia, MocciaAlden, MohmJohannes, OstermannHelmut, PabstThomas, PlütschowAnnette, RosenwaldAndreas, SöklerMartin, ThiemerJulia, ToppMax S, VogelhuberMartin, WilhelmMartin, ZijlstraJosée M, von TresckowBastian

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated whether radiation therapy could be omitted for patients with early-stage Hodgkin lymphoma who respond well to chemotherapy. The study aimed to determine if a specific combination of chemotherapy regimens could be effective enough to avoid radiation therapy, which can have long-term side effects, especially for young adults.
Paper Details　
Original Abstract of the Article :
Combined-modality treatment consisting of chemotherapy and consolidation radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. However, the use of radiotherapy can have long-term sequelae, which is of particular concern, as Hodgkin lymphoma is frequently diagn...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(20)30601-X

データ提供：米国国立医学図書館（NLM）

Radiotherapy Omission in Hodgkin Lymphoma: A New Dawn?

Hodgkin lymphoma, a cancer affecting the lymphatic system, often requires a combined approach of chemotherapy and radiation therapy. This study, conducted by the German Hodgkin Study Group, explores a potential paradigm shift in the treatment of early-stage Hodgkin lymphoma. The researchers sought to determine if radiotherapy could be safely omitted in patients who achieved a complete metabolic response after receiving two cycles of escalated doses of etoposide, cyclophosphamide, and doxorubicin (eBEACOPP) plus two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy. This study, much like a desert explorer charting uncharted territory, sought to establish a new path for treating this disease.

Metabolic Response: A Key Indicator for Radiotherapy Omission

The study's findings suggest a potential shift in standard practice. Patients who achieved a complete metabolic response after chemotherapy, measured through a PET scan, may be able to avoid the potential long-term side effects of radiotherapy. This approach, akin to a desert traveler choosing a well-worn path, could lead to improved quality of life for patients.

Implications for Hodgkin Lymphoma Treatment

This study, like a desert oasis providing respite from the harsh environment, offers a glimmer of hope for individuals diagnosed with early-stage unfavorable Hodgkin lymphoma. The findings suggest that radiotherapy may not be necessary for all patients, potentially reducing the long-term health risks associated with this treatment. Future research should explore the long-term outcomes of this approach to further solidify its potential benefits.

Dr.Camel's Conclusion

This research is like a beacon in the vast desert of Hodgkin lymphoma treatment. The potential to omit radiotherapy for select patients offers a promising path towards personalized medicine and enhanced patient outcomes. However, it's important to remember that, like the desert itself, this field is constantly evolving. We must continue to explore the landscape of Hodgkin lymphoma treatment, seeking new pathways to effectively manage this complex disease and improve the lives of those affected.

Date :
  1. Date Completed 2021-02-18
  2. Date Revised 2022-03-25
Further Info :

Pubmed ID

33539742

DOI: Digital Object Identifier

10.1016/S1470-2045(20)30601-X

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.